Fresh thinking is redefining where and how early-phase clinical trials take shape. In this edition: LATAM aims to quadruple its clinical trial footprint.
clinical trial · FDA · MedTech · data
Fresh thinking is redefining where and how early-phase clinical trials take shape. In this edition:
LATAM aims to quadruple its clinical trial footprint. FDA guidance for 2026 spotlights data, devices, and agility. Brazil re-emerges as a strategic R&D and investment hub.
Explore how strategy, science, and regions are converging. 👇
← All Global Trial Accelerators editions · Contact bioaccess®